At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses the trial design and results of the phase 3 PERSIST-1 trial of pacritinib, versus best available therapy in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia-myelofibrosis.
Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis
26th June 2015
Hematology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?